IBDEI1ME ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,27489,1,4,0)
 ;;=4^N01.2
 ;;^UTILITY(U,$J,358.3,27489,2)
 ;;=^5015503
 ;;^UTILITY(U,$J,358.3,27490,0)
 ;;=N01.3^^106^1363^65
 ;;^UTILITY(U,$J,358.3,27490,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27490,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffus mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,27490,1,4,0)
 ;;=4^N01.3
 ;;^UTILITY(U,$J,358.3,27490,2)
 ;;=^5015504
 ;;^UTILITY(U,$J,358.3,27491,0)
 ;;=N01.4^^106^1363^64
 ;;^UTILITY(U,$J,358.3,27491,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27491,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffus endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,27491,1,4,0)
 ;;=4^N01.4
 ;;^UTILITY(U,$J,358.3,27491,2)
 ;;=^5015505
 ;;^UTILITY(U,$J,358.3,27492,0)
 ;;=N01.5^^106^1363^68
 ;;^UTILITY(U,$J,358.3,27492,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27492,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffuse mesangiocap glomrlneph
 ;;^UTILITY(U,$J,358.3,27492,1,4,0)
 ;;=4^N01.5
 ;;^UTILITY(U,$J,358.3,27492,2)
 ;;=^5015506
 ;;^UTILITY(U,$J,358.3,27493,0)
 ;;=N01.6^^106^1363^63
 ;;^UTILITY(U,$J,358.3,27493,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27493,1,3,0)
 ;;=3^Rapidly progr neph synd w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,27493,1,4,0)
 ;;=4^N01.6
 ;;^UTILITY(U,$J,358.3,27493,2)
 ;;=^5015507
 ;;^UTILITY(U,$J,358.3,27494,0)
 ;;=N01.7^^106^1363^66
 ;;^UTILITY(U,$J,358.3,27494,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27494,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffuse crescentic glomrlneph
 ;;^UTILITY(U,$J,358.3,27494,1,4,0)
 ;;=4^N01.7
 ;;^UTILITY(U,$J,358.3,27494,2)
 ;;=^5015508
 ;;^UTILITY(U,$J,358.3,27495,0)
 ;;=N01.8^^106^1363^71
 ;;^UTILITY(U,$J,358.3,27495,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27495,1,3,0)
 ;;=3^Rapidly progr neph synd w/ oth morphologic changes
 ;;^UTILITY(U,$J,358.3,27495,1,4,0)
 ;;=4^N01.8
 ;;^UTILITY(U,$J,358.3,27495,2)
 ;;=^5015509
 ;;^UTILITY(U,$J,358.3,27496,0)
 ;;=N01.9^^106^1363^72
 ;;^UTILITY(U,$J,358.3,27496,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27496,1,3,0)
 ;;=3^Rapidly progr neph synd w/ unsp morphologic changes
 ;;^UTILITY(U,$J,358.3,27496,1,4,0)
 ;;=4^N01.9
 ;;^UTILITY(U,$J,358.3,27496,2)
 ;;=^5015510
 ;;^UTILITY(U,$J,358.3,27497,0)
 ;;=N02.0^^106^1363^80
 ;;^UTILITY(U,$J,358.3,27497,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27497,1,3,0)
 ;;=3^Recurrent & perst hematur w/ minor glomerular abnlt
 ;;^UTILITY(U,$J,358.3,27497,1,4,0)
 ;;=4^N02.0
 ;;^UTILITY(U,$J,358.3,27497,2)
 ;;=^5015511
 ;;^UTILITY(U,$J,358.3,27498,0)
 ;;=N02.1^^106^1363^79
 ;;^UTILITY(U,$J,358.3,27498,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27498,1,3,0)
 ;;=3^Recurrent & perst hematur w/ focal & seg glomerular lesions
 ;;^UTILITY(U,$J,358.3,27498,1,4,0)
 ;;=4^N02.1
 ;;^UTILITY(U,$J,358.3,27498,2)
 ;;=^5015512
 ;;^UTILITY(U,$J,358.3,27499,0)
 ;;=N02.2^^106^1363^77
 ;;^UTILITY(U,$J,358.3,27499,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27499,1,3,0)
 ;;=3^Recurrent & perst hematur w/ diffuse membranous glomrlneph
 ;;^UTILITY(U,$J,358.3,27499,1,4,0)
 ;;=4^N02.2
 ;;^UTILITY(U,$J,358.3,27499,2)
 ;;=^5015513
 ;;^UTILITY(U,$J,358.3,27500,0)
 ;;=N02.3^^106^1363^74
 ;;^UTILITY(U,$J,358.3,27500,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27500,1,3,0)
 ;;=3^Recur & perst hematur w/ diffus mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,27500,1,4,0)
 ;;=4^N02.3
 ;;^UTILITY(U,$J,358.3,27500,2)
 ;;=^5015514
 ;;^UTILITY(U,$J,358.3,27501,0)
 ;;=N02.4^^106^1363^73
 ;;^UTILITY(U,$J,358.3,27501,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27501,1,3,0)
 ;;=3^Recur & perst hematur w/ diffus endocaplry prolif glomrlneph
